Foley Balloon Study for Cervical Ripening - Cost Comparison Between Outpatient and Inpatient Cervical Ripening

Sponsor
Lehigh Valley Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05506631
Collaborator
(none)
412
1
2
12
34.4

Study Details

Study Description

Brief Summary

The objective of this study is to determine the impact of outpatient cervical ripening with transcervical balloon placement for induction of labor at term on the length and cost of inpatient hospitalization when compared to inpatient cervical ripening.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Outpatient Foley balloon placement
  • Procedure: Inpatient Foley Balloon placement
N/A

Detailed Description

The objective of the study is to determine the impact of outpatient cervical ripening with transcervical balloon placement for induction of labor at term on the length and cost of inpatient hospitalization when compared to inpatient cervical ripening.

Specific Aims

In conducting this study, the investigators will accomplish the following specific aim:

To compare the length of inpatient care for women undergoing cervical ripening with a transcervical Foley placed in the outpatient vs. inpatient setting prior to induction of labor.

  • Primary outcomes of interest

  • The length of time (measured in minutes) spent on the inpatient unit (L&D) from admission for cervical ripening and/or labor induction until delivery.

Outpatient arm:

Time for the participants in the outpatient group will be measured from the time the participant is admitted to the hospital for induction of labor until she delivers.

Inpatient arm:

Time for the participant in the inpatient group will be measured from the time the participant is admitted to the hospital for cervical ripening with balloon placement and induction until she delivers.

Time from admission to L&D until delivery = total INPATIENT until delivery (hours)

• Cost Analysis

Cost/charges will be calculated for the time spent in the outpatient and inpatient unit for both randomization groups.

Cost will be based on information obtained from Enterprise Analytics charges for the time each participant spends in outpatient care, inpatient care, hospitalized from admission to the L&D unit to delivery.

The investigators will report on the delta/difference in average costs of outpatient and inpatient care between the outpatient and inpatient arms of the study.

Information will be obtained from the finance department at LVHN.

  • Secondary outcomes of interest to be compared by randomization groups include:

  • maternal outcomes

  • mode of delivery, chorioamnionitis, endometritis, placental abruption, urinary tract infection, preeclampsia, wound infection, venous thromboembolism, maternal treatment with postpartum antibiotics

  • neonatal outcomes

  • neonatal birthweight, Apgar scores, admission to the neonatal intensive care unit (ICU), neonatal ICU length of stay, neonatal hypoglycemia, neonatal sepsis, neonatal seizures, meconium aspiration, intubation for respiratory support, neonatal length of stay (total), umbilical cord gas pH, neonatal death or stillbirth

  • dosing of narcotic medications before regional anesthesia

  • total oxytocin infusion dosing

  • total length of stay for mothers and neonates

Study Design

Study Type:
Interventional
Anticipated Enrollment :
412 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled trialRandomized controlled trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Cost of Inpatient Care for Women Undergoing Outpatient vs. Inpatient Transcervical Balloon Cervical Ripening for Induction of Labor at Term
Actual Study Start Date :
Nov 1, 2021
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Outpatient cervical ripening

Placement of transcervical Foley balloon for cervical ripening in outpatient setting

Procedure: Outpatient Foley balloon placement
Cervical ripening with balloon placement in the outpatient setting

Active Comparator: Inpatient cervical ripening

Placement of transcervical Foley balloon for cervical ripening in inpatient setting

Procedure: Inpatient Foley Balloon placement
Cervical ripening with balloon placement in the inpatient setting

Outcome Measures

Primary Outcome Measures

  1. The length of time (measured in minutes) spent on the inpatient unit from admission from cervical ripening and/or labor induction until delivery. [12 months]

    The length of time (measured in minutes) spent on the inpatient unit (L&D) from admission for cervical ripening and/or labor induction until delivery.

  2. Cost Analysis in dollars Cost/charges will be calculated for the time spent in the outpatient and inpatient unit for both randomization groups. [12 months]

    Cost Analysis in dollars Cost/charges will be calculated for the time spent in the outpatient and inpatient unit for both randomization groups. Cost will be based on information obtained from Enterprise Analytics charges for the time each woman spends in outpatient care, inpatient care, hospitalized from admission to the L&D unit to delivery.

Secondary Outcome Measures

  1. Delivery [12 months]

    Mode of Delivery

  2. Maternal state [12 months]

    Maternal outcomes

  3. Neonatal State [12 months]

    Neonatal outcomes

  4. Maternal Adverse events [12 months]

    Maternal Adverse events such as chorioamnionitis; endometritis; placental abruption; urinary tract infection; preeclampsia,; wound infection; venous thromboembolism; need for post partum antibiotics

  5. Neonatal adverse events [12 months]

    Neonatal Adverse events such as: hypoglycemia; sepsis; seizures; meconium aspiration; respiratory failure; death

  6. Birthweight [12 months]

    neonatal birthweight in kilograms

  7. Apgar Score [12 months]

    neonatal Apgar score- score of 1-10

  8. ICU Length of stay [12 months]

    neonatal ICU length of stay in days

  9. Total Length of stay [12 months]

    neonatal Inpatient length of stay in days

  10. Cord PH [12 months]

    Umbilical cord gas PH as reported

  11. Narcotic dosing [12 months]

    Maternal dosing of narcotic medications before regional anesthesia

  12. Oxytocin dosing [12 months]

    Oxytocin dose per unit

  13. Maternal length of stay [12 months]

    Maternal inpatient length of stay in days

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 39 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes

Inclusion Criteria

  • Pregnant women at ≥39 weeks gestation by reliable dating criteria as determined by the American College of Obstetricians and Gynecologists

  • Scheduled induction of labor with indication and timing supported by Lehigh Valley Health Network -Labor and Delivery Units (Cedar Crest & Muhlenberg)

  • Singleton gestation

  • Cephalic presentation

  • Amniotic fluid index normal

  • Formal prenatal ultrasound during the pregnancy documenting the absence of placenta previa

  • Bishop score <6 and cervical dilation <3cm at the time of decision to induce labor

  • The woman is able to give appropriate consent and has undergone an informed consent process.

  • Maternal age ≥ 18 years old at the time of consent

  • English speaking

Exclusion Criteria

  • Undergoing outpatient antenatal testing for any medical or obstetric condition

  • Need for inpatient observation or continuous fetal monitoring during their cervical ripening

  • New diagnosis requiring immediate hospitalization for monitoring (such as new onset hypertensive disease of pregnancy)

  • Vaginal bleeding

  • Active labor

  • Premature rupture of membranes

  • Uterine tachysystole (>5 contractions in 10 minutes)

  • Non-reassuring fetal heart tracing before Foley placement

  • Intrauterine fetal demise diagnosed after enrollment and before placement of balloon

  • Contraindication to vaginal delivery, relative or absolute (i.e. transfundal uterine surgery)

  • Abnormal placentation including a low lying placenta

  • Prior cesarean delivery

  • Known fetal major anomaly

  • Human immunodeficiency virus, Hepatitis C, or active herpes infection

  • Maternal cardiopulmonary disease requiring cardiac monitoring during labor

  • Pregestational diabetes or GDMA2

  • Rh isoimmunization

  • Non-English speaking

  • BMI > 40

  • Distance from the hospital over 60 minutes by car, unreliable communication via telephone, or unreliable transportation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Lehigh Valley Health Network Allentown Pennsylvania United States 18105

Sponsors and Collaborators

  • Lehigh Valley Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Joanne Quinones, MD, Vice Chair Research, Dept OBGYN, Lehigh Valley Health Network, Lehigh Valley Hospital
ClinicalTrials.gov Identifier:
NCT05506631
Other Study ID Numbers:
  • 00000949
First Posted:
Aug 18, 2022
Last Update Posted:
Aug 18, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Joanne Quinones, MD, Vice Chair Research, Dept OBGYN, Lehigh Valley Health Network, Lehigh Valley Hospital

Study Results

No Results Posted as of Aug 18, 2022